CC BY 4.0 · Rev Bras Ginecol Obstet 2023; 45(08): e439-e446
DOI: 10.1055/s-0043-1772184
Original Article
High Risk Pregnancy/Covid-19

The Effect of SARS-CoV-2 İnfection on Perinatal Outcomes in Hypertensive Disorders of Pregnancy

O efeito da infecção por SARS-CoV-2 no perinatal resultados em distúrbios hipertensivos de gravidez
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
,
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
,
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
,
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
,
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
,
1   Division of Perinatology, Department of Obstetrics and Gynecology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
2   Division of Perinatology, Department of Obstetrics and Gynecology, University of Health Sciences, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey.
› Institutsangaben

Abstract

Objective To evaluate the fetal and maternal effects of the severe acute respiratory syndrome virus 2 (SARS-CoV-2) infection in women with hypertensive disorders of pregnancy.

Methods Patients with hypertensive disorders of pregnancy and SARS-CoV-2 polymerase chain reaction (PCR) positivity (n = 55) were compared with cases with similar characteristics and PCR negativity (n = 53). The study group was further divided into two groups as severe (n = 11) and nonsevere (n = 44) coronavirus disease 2019 (COVID-19). The groups were compared in terms of clinical characteristics and perinatal outcomes.

Results The study and control groups were similar in terms of maternal age, parity, gestational age at diagnosis, type of hypertensive disorders, magnesium sulfate administration rate, gestational age at birth, birth weight, Apgar scores, and maternal complications. However, all cases of fetal loss (n = 6) were observed in the SARS-CoV-2 positive group (p = 0.027). From the 6 cases, there were 5 in the nonsevere group and 1 patient in the severe SARS-CoV-2 positive group. Moreover, higher rates of maternal complications, lower oxygen saturation values, and intensive care unit admissions were observed in the severe COVID-19 group.

Conclusion Physicians should be cautious about the management of hypertensive disorders of pregnancy cases with SARS-CoV-2 positivity. Fetal loss seems to be more common in cases with SARS-CoV-2 positivity and severe COVID-19 seems to be associated with higher rates of maternal complications. Close follow-up for fetal wellbeing and active management of severe cases in terms of maternal complications seem to be favorable.

Contributions

All authors have read and approved the final article. All authors contributed to the following sections of the article and fulfilled the conditions for being an article writer. Tanaçan: Data analysis, Manuscript writing, Study concept, design. Sakcak: Data collection, Study concept, design. Şahin: Manuscript editing, Study concept, design. Farisoğulları: Manuscript writing, Data collection, Project development, Study concept, design. Kara: Data analysis, Project development, Study concept, design. Denizli: Manuscript writing, Study concept, design.




Publikationsverlauf

Eingereicht: 02. November 2022

Angenommen: 01. Februar 2023

Artikel online veröffentlicht:
08. September 2023

© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • References

  • 1 World Health Organization. 2020 , March 11). WHO Director-General's remarks at the media briefing on COVID-19–11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020
  • 2 Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. Acta Obstet Gynecol Scand 2020; 99 (07) 839-847
  • 3 Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ. et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020; 251 (03) 228-248
  • 4 Fabre M, Calvo P, Ruiz-Martinez S, Peran M, Oros D, Medel-Martinez A. et al. Frequent Placental SARS-CoV-2 in Patients with COVID-19-Associated Hypertensive Disorders of Pregnancy. Fetal Diagn Ther 2021; 48 (11-12): 801-811
  • 5 Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis 2013; 20 (03) 229-239
  • 6 Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001; 14 (6 Pt 2): 178S-185S
  • 7 Heimrath J, Czekański A, Krawczenko A, Duś D. [The role of endothelium in the pathogenesis of pregnancy-induced hypertension]. Postepy Hig Med Dosw 2007; 61: 48-57
  • 8 Papageorghiou AT, Deruelle P, Gunier RB, Rauch S, García-May PK, Mhatre M. et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol 2021; 225 (03) 289.e1-289.e17
  • 9 Wang X, Tan L, Wang X, Liu W, Lu Y, Cheng L, Sun Z. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. Int J Infect Dis 2020; 94: 107-109
  • 10 World Health Organization. 2020 Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf . Accessed July 30, 2022
  • 11 American College of O. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122 (05) 1122-1131
  • 12 Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol 2011; 159 (01) 77-82
  • 13 Theilen LH, Meeks H, Fraser A, Esplin MS, Smith KR, Varner MW. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol 2018; 219 (01) 107.e1-107.e6
  • 14 Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T. et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019. MMWR Morb Mortal Wkly Rep 2022; 71 (17) 585-591
  • 15 Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021; 193 (16) E540-E548
  • 16 Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y. et al. Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet Gynecol 2020; 223 (06) 914.e1-914.e15
  • 17 Sutjipto S, Lee PH, Tay JY, Mendis SM, Abdad MY, Marimuthu K. et al; National Centre for Infectious Diseases COVID-19 Outbreak Research Team. The effect of sample site, illness duration, and the presence of pneumonia on the detection of SARS-CoV-2 by real-time reverse transcription PCR. Open Forum Infect Dis 2020; 7 (09) ofaa335
  • 18 Pettirosso E, Giles M, Cole S, Rees M. COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission. Aust N Z J Obstet Gynaecol 2020; 60 (05) 640-659
  • 19 Di Mascio D, Sen C, Saccone G, Galindo A, Grünebaum A, Yoshimatsu J. et al. Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19. J Perinat Med 2020; 48 (09) 950-958
  • 20 Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G, Fei C. Potential influence of COVID-19/ACE2 on the female reproductive system. Mol Hum Reprod 2020; 26 (06) 367-373
  • 21 Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15 (04) 166-169
  • 22 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367 (6485) 1444-1448
  • 23 Choi H, Kang JY, Yoon HS, Han SS, Whang CS, Moon IG. et al. Association of Angiotensin-converting enzyme and angiotensinogen gene polymorphisms with preeclampsia. J Korean Med Sci 2004; 19 (02) 253-257
  • 24 Bandara S, Ruwanpathirana A, Nagodawithana D, Alwis S. Hypertensive Crisis in Pregnancy with COVID19: Confirmed with rt-PCR for Nasopharyngeal Swab. Case Rep Obstet Gynecol 2020; 2020: 8868952
  • 25 Patberg ET, Adams T, Rekawek P, Vahanian SA, Akerman M, Hernandez A. et al. Coronavirus disease 2019 infection and placental histopathology in women delivering at term. Am J Obstet Gynecol 2021; 224 (04) 382.e1-382.e18 Erratum in: Am J Obstet Gynecol. 2021 Jun 10; PMID: 33091406; PMCID: PMC7571377
  • 26 Maraschini A, Corsi E, Salvatore MA, Donati S. ItOSS COVID-19 Working Group. Coronavirus and birth in Italy: results of a national population-based cohort study. Ann Ist Super Sanita 2020; 56 (03) 378-389